glimepiride has been researched along with Obesity in 14 studies
glimepiride: structure given in first source
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)." | 5.48 | Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018) |
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 5.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| "To assess the pharmacokinetic characteristics of glimepiride and its metabolites in normal-weight and morbidly obese patients with type 2 diabetes to determine whether the pharmacokinetics of glimepiride are altered by obesity." | 5.11 | Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. ( Chi, EM; Lehr, KH; Shukla, UA, 2004) |
| " We report a case of a 71-year-old woman with type 2 diabetes on dapagliflozin, presenting with foul-smelling discharge and a large abscess in the perianal area." | 4.02 | Fournier's gangrene with dapagliflozin in a rural hospital: a case report. ( Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y, 2021) |
| "Seventy drug-naïve patients with type 2 diabetes (mean age, 52." | 3.30 | Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. ( Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M, 2023) |
| "In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin." | 2.74 | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. ( Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M, 2009) |
| " A dosage of 70/30 insulin before supper was titrated, seeking fasting capillary blood glucose (FBG) 120 mg/dl (6." | 2.69 | Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. ( Riddle, MC; Schneider, J, 1998) |
| "15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide)." | 1.51 | Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. ( Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE, 2019) |
| "Men with type 2 diabetes (T2D) and obesity are often characterised by low testosterone (T)." | 1.48 | Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity. ( Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ, 2018) |
| "Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes." | 1.39 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. ( Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, S | 1 |
| Sohn, M | 1 |
| Florez, JC | 1 |
| Nauck, MA | 1 |
| Ahn, J | 1 |
| Elbeddini, A | 1 |
| Tayefehchamani, Y | 1 |
| Davey, M | 1 |
| Gallinger, J | 1 |
| Hooda, N | 1 |
| Aly, A | 1 |
| Erickson, D | 1 |
| Lee, S | 1 |
| Shao, N | 1 |
| Yu, XY | 1 |
| Yu, YM | 1 |
| Li, BW | 1 |
| Pan, J | 1 |
| Wu, WH | 1 |
| Zhang, HJ | 1 |
| Ma, XF | 1 |
| Hao, M | 1 |
| Kuang, HY | 1 |
| Savchenko, LG | 1 |
| Digtiar, NI | 1 |
| Selikhova, LG | 1 |
| Kaidasheva, EI | 1 |
| Shlykova, OA | 1 |
| Vesnina, LE | 1 |
| Kaidashev, IP | 1 |
| El-Haggar, SM | 1 |
| Farrag, WF | 1 |
| Kotkata, FA | 1 |
| Nauck, M | 1 |
| Frid, A | 1 |
| Hermansen, K | 1 |
| Shah, NS | 1 |
| Tankova, T | 1 |
| Mitha, IH | 1 |
| Zdravkovic, M | 2 |
| Düring, M | 1 |
| Matthews, DR | 1 |
| Al-Jebawi, AF | 1 |
| Lee, YH | 1 |
| Lee, BW | 1 |
| Chun, SW | 1 |
| Cha, BS | 1 |
| Lee, HC | 1 |
| Horowitz, M | 1 |
| Flint, A | 1 |
| Jones, KL | 1 |
| Hindsberger, C | 1 |
| Rasmussen, MF | 1 |
| Kapitza, C | 1 |
| Doran, S | 1 |
| Jax, T | 1 |
| Chapman, IM | 1 |
| Darsalia, V | 1 |
| Ortsäter, H | 1 |
| Olverling, A | 1 |
| Darlöf, E | 1 |
| Wolbert, P | 1 |
| Nyström, T | 1 |
| Klein, T | 1 |
| Sjöholm, Å | 1 |
| Patrone, C | 1 |
| Mori, Y | 1 |
| Komiya, H | 1 |
| Kurokawa, N | 1 |
| Tajima, N | 1 |
| Shukla, UA | 1 |
| Chi, EM | 1 |
| Lehr, KH | 1 |
| Inukai, K | 1 |
| Watanabe, M | 1 |
| Nakashima, Y | 1 |
| Sawa, T | 1 |
| Takata, N | 1 |
| Tanaka, M | 1 |
| Kashiwabara, H | 1 |
| Yokota, K | 1 |
| Suzuki, M | 1 |
| Kurihara, S | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Riddle, MC | 1 |
| Schneider, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interest of GLP1 Analogues (aGLP1) in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease (IBD)[NCT05196958] | 20 participants (Anticipated) | Interventional | 2022-01-25 | Recruiting | |||
| Chinese People's Liberation Army General Hospital[NCT02930265] | 400 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | |||
| Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With[NCT00318461] | Phase 3 | 1,091 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients[NCT04529278] | Phase 2 | 18 participants (Actual) | Interventional | 2021-01-18 | Active, not recruiting | ||
| A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)[NCT03421119] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-06-20 | Not yet recruiting | ||
| Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.[NCT05419726] | 20 participants (Anticipated) | Observational | 2023-02-01 | Recruiting | |||
| A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo[NCT01511692] | Phase 1 | 43 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From the Health Insurance Review and Assessment Service Database[NCT05817097] | 22,119 participants (Anticipated) | Observational | 2023-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 104
| Intervention | percentage point (%point) (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | 64.48 |
| Lira 1.2 + Met | 27.30 |
| Lira 1.8 + Met | 17.81 |
| Met Mono | -7.89 |
| Met + Glim | 11.25 |
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 26
| Intervention | percentage point (%point) (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | 20.45 |
| Lira 1.2 + Met | 20.33 |
| Lira 1.8 + Met | 26.12 |
| Met Mono | -1.63 |
| Met + Glim | 24.68 |
Change in body weight from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -2.07 |
| Lira 1.2 + Met | -3.03 |
| Lira 1.8 + Met | -2.91 |
| Met Mono | -1.80 |
| Met + Glim | 0.70 |
Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.78 |
| Lira 1.2 + Met | -2.58 |
| Lira 1.8 + Met | -2.79 |
| Met Mono | -1.51 |
| Met + Glim | 0.95 |
Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.80 |
| Lira 1.2 + Met | -1.20 |
| Lira 1.8 + Met | -1.18 |
| Met Mono | 0.75 |
| Met + Glim | -0.64 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.13 |
| Lira 1.2 + Met | -1.63 |
| Lira 1.8 + Met | -1.68 |
| Met Mono | 0.40 |
| Met + Glim | -1.31 |
Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | percentage of total haemoglobin (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.36 |
| Lira 1.2 + Met | -0.56 |
| Lira 1.8 + Met | -0.58 |
| Met Mono | 0.25 |
| Met + Glim | -0.50 |
Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | Percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.69 |
| Lira 1.2 + Met | -0.97 |
| Lira 1.8 + Met | -1.00 |
| Met Mono | 0.09 |
| Met + Glim | -0.98 |
Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.59 |
| Lira 1.2 + Met | -2.22 |
| Lira 1.8 + Met | -2.10 |
| Met Mono | -0.43 |
| Met + Glim | -1.80 |
Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.68 |
| Lira 1.2 + Met | -2.33 |
| Lira 1.8 + Met | -2.57 |
| Met Mono | -0.62 |
| Met + Glim | -2.46 |
"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.27 |
| Lira 1.2 + Met | -0.56 |
| Lira 1.8 + Met | -0.44 |
| Met Mono | -0.20 |
| Met + Glim | -0.29 |
"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/l (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.23 |
| Lira 1.2 + Met | -0.40 |
| Lira 1.8 + Met | -0.56 |
| Met Mono | -0.44 |
| Met + Glim | -0.44 |
Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-104
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| All | Major | Minor | Symptoms only | |
| Lira 0.6 + Met | 52 | 0 | 23 | 29 |
| Lira 1.2 + Met | 51 | 1 | 26 | 24 |
| Lira 1.8 + Met | 49 | 0 | 22 | 27 |
| Met + Glim | 524 | 0 | 284 | 240 |
| Met Mono | 18 | 0 | 6 | 12 |
Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-26
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Lira 0.6 + Met | 0 | 15 | 17 |
| Lira 1.2 + Met | 0 | 3 | 7 |
| Lira 1.8 + Met | 0 | 9 | 22 |
| Met + Glim | 0 | 136 | 175 |
| Met Mono | 0 | 6 | 10 |
8 trials available for glimepiride and Obesity
6 other studies available for glimepiride and Obesity
| Article | Year |
|---|---|
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes | 2021 |
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Com | 2018 |
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression | 2019 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Rem | 2010 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglyc | 2013 |
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2004 |